Literature DB >> 24639234

Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.

Hongtao Xu1, James Paxton, Joanne Lim, Yan Li, Wenli Zhang, Linda Duxfield, Zimei Wu.   

Abstract

PURPOSE: The objective of this study was to develop high-content gemcitabine PEGylated liposomes to reverse gemcitabine resistance in pancreatic tumour cells. The mechanism of drug loading into liposomes was also investigated.
METHODS: To increase the drug entrapment efficiency (EE) and drug loading (DL), a novel passive loading approach named Small Volume Incubation method (SVI) was developed and compared to the reverse phase evaporation (REV) and remote loading methods. The in vitro cytotoxicity was evaluated using MIA PaCa-2 and Panc-1 cell lines.
RESULTS: The EE for remote loading was 12.3 ± 0.3%, much lower than expected and a burst release was observed with the resultant liposomes. Using the optimized SVI method, increased EE (37 ± 1%) and DL (4%, w/w) were obtained. The liposomes (200 ± 5 nm) showed minimal drug leakage, good stability, and significant improvement in cytotoxicity to the gemcitabine-resistant pancreatic cancer cell lines.
CONCLUSIONS: Remote loading was not suitable for loading gemcitabine into liposomes. pKa > 4.6 for basic drugs and intra-liposomal precipitation of loaded compounds were suggested as an additional requirement to the current criteria for remote loading using ammonium sulphate gradient (pKa < 11). High DL is essential for liposomes to reverse gemcitabine resistance in pancreatic cell lines.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24639234     DOI: 10.1007/s11095-014-1353-z

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  36 in total

1.  Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties.

Authors:  Daniel Zucker; David Marcus; Yechezkel Barenholz; Amiram Goldblum
Journal:  J Control Release       Date:  2009-06-07       Impact factor: 9.776

2.  Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.

Authors:  Shadan Ali; Aamir Ahmad; Sanjeev Banerjee; Subhash Padhye; Kristin Dominiak; Jacqueline M Schaffert; Zhiwei Wang; Philip A Philip; Fazlul H Sarkar
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

Review 3.  Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects.

Authors:  Kazuo Maruyama
Journal:  Adv Drug Deliv Rev       Date:  2010-10-28       Impact factor: 15.470

4.  Phase structure of liposome in lipid mixtures.

Authors:  Tianxi Zhang; Yuzhuo Li; Anja Mueller
Journal:  Chem Phys Lipids       Date:  2011-08-19       Impact factor: 3.329

5.  Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes.

Authors:  Maria Grazia Calvagno; Christian Celia; Donatella Paolino; Donato Cosco; Michelangelo Iannone; Francesco Castelli; Patrizia Doldo; Massimo Frest
Journal:  Curr Drug Deliv       Date:  2007-01       Impact factor: 2.565

6.  Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer.

Authors:  Ralph Graeser; Christian Bornmann; Norbert Esser; Vittorio Ziroli; Peter Jantscheff; Clemens Unger; Ulrich T Hopt; Christoph Schaechtele; Ernst von Dobschuetz; Ulrich Massing
Journal:  Pancreas       Date:  2009-04       Impact factor: 3.327

7.  Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice.

Authors:  In-Young Kim; Young-Sook Kang; Doo Sung Lee; Heon-Joo Park; Eun-Kyung Choi; Yu-Kyoung Oh; Hye-Jung Son; Jin-Seok Kim
Journal:  J Control Release       Date:  2009-07-17       Impact factor: 9.776

Review 8.  Gemcitabine in the treatment of metastatic pancreatic cancer.

Authors:  Andreas Hilbig; Helmut Oettle
Journal:  Expert Rev Anticancer Ther       Date:  2008-04       Impact factor: 4.512

Review 9.  Role of gemcitabine in cancer therapy.

Authors:  L Toschi; G Finocchiaro; S Bartolini; V Gioia; F Cappuzzo
Journal:  Future Oncol       Date:  2005-02       Impact factor: 3.404

10.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Authors:  J L Abbruzzese; R Grunewald; E A Weeks; D Gravel; T Adams; B Nowak; S Mineishi; P Tarassoff; W Satterlee; M N Raber
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

View more
  14 in total

1.  Development of Liposomal Gemcitabine with High Drug Loading Capacity.

Authors:  Hassan Tamam; Jinho Park; Hytham H Gadalla; Andrea R Masters; Jelan A Abdel-Aleem; Sayed I Abdelrahman; Aly A Abdelrahman; L Tiffany Lyle; Yoon Yeo
Journal:  Mol Pharm       Date:  2019-06-14       Impact factor: 4.939

2.  Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug.

Authors:  Hongtao Xu; James W Paxton; Zimei Wu
Journal:  Pharm Res       Date:  2015-02-06       Impact factor: 4.200

3.  PEG-Benzaldehyde-Hydrazone-Lipid Based PEG-Sheddable pH-Sensitive Liposomes: Abilities for Endosomal Escape and Long Circulation.

Authors:  Manju Kanamala; Brian D Palmer; Hamidreza Ghandehari; William R Wilson; Zimei Wu
Journal:  Pharm Res       Date:  2018-05-31       Impact factor: 4.200

4.  Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells.

Authors:  Hongtao Xu; James W Paxton; Zimei Wu
Journal:  Pharm Res       Date:  2016-03-10       Impact factor: 4.200

5.  Strategies to maximize liposomal drug loading for a poorly water-soluble anticancer drug.

Authors:  Wenli Zhang; Guangji Wang; James R Falconer; Bruce C Baguley; John P Shaw; Jianping Liu; Hongtao Xu; Esther See; Jianguo Sun; Jiye Aa; Zimei Wu
Journal:  Pharm Res       Date:  2014-10-30       Impact factor: 4.200

6.  Tumor-specific delivery of gemcitabine with activatable liposomes.

Authors:  Samantha T Tucci; Azadeh Kheirolomoom; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; Josquin Foiret; Neil E Hubbard; Alexander D Borowsky; Mo Baikoghli; R Holland Cheng; Katherine W Ferrara
Journal:  J Control Release       Date:  2019-07-10       Impact factor: 9.776

7.  Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine.

Authors:  Yuanfen Liu; Hassan Tamam; Yoon Yeo
Journal:  AAPS PharmSciTech       Date:  2017-10-02       Impact factor: 3.246

8.  Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer.

Authors:  Xiangsheng Liu; Allen Situ; Yanan Kang; Katie Rose Villabroza; Yupei Liao; Chong Hyun Chang; Timothy Donahue; Andre E Nel; Huan Meng
Journal:  ACS Nano       Date:  2016-02-09       Impact factor: 15.881

9.  Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.

Authors:  Zhongyuan Tang; Weiwei Feng; Yiqing Yang; Qun Wang
Journal:  Drug Des Devel Ther       Date:  2019-09-17       Impact factor: 4.162

10.  Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.

Authors:  Mohamed Wehbe; Lihong Wang-Bishop; Kyle W Becker; Daniel Shae; Jessalyn J Baljon; Xinyi He; Plamen Christov; Kelli L Boyd; Justin M Balko; John T Wilson
Journal:  J Control Release       Date:  2020-11-12       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.